Psych Flashcards
clozapine REMS monitoring
Risk of severe neutropenia (< 500).
Initiate treatment if ANC > 1500 for general population or > 1000 for BEN patients and monitor weekly for 6 months, then every other week for 6 months, then monthly.
If ANC < 500, interrupt treatment and do not rechallenge. If rechallenged, treat as a “new” patient.
Highest risk of QTc prolongation (FGA/SGA)
FGA: chlorpromazine, haloperidol (avoid IV use), thioridazine
SGA: clozapine, ziprasidone, and iloperidone
Akathisia
restlessness - lower dose or change to an SGA with lower EPS risk.
Insufficient data on use of propranolol, but it is used
BZD’s can reduce sx but beware if substance abuse disorder.
FDA approved tx for tardive dyskinesia
Valbenazine, deutetrabenazine (black box warning for increased risk of suicide)
Neuroleptic malignant syndrome
Treat with bromocriptine or dantrolene. High mortality rate.
Clozapine
Neutropenia
Seizures
OH/bradycardia/syncope
Myocarditis and cardiomyopathy
Can add lamotrigine in patients on clozapine with a partial response schizophrenia
Metabolized by CYP1A2, which is induced by smoking. So if smoking cessation, causes supratherapeutic levels.
Aripiprazole
Akathisia
Pathological gambling
LAI requires 21 day overlap with PO agent
Low risk of hyperprolactinemia or EPS
Asenapine
SL formulation
Hypersentivity reactions
Avoid eating or drinking for 10 minutes after administration
High risk of sedation/orthostasis
Brexpiprazole
Schizopherenia/MDD
Akathisia, weight gain, and somnolence
Compulsive behaviors
Cariprazine
Mixed/manic episodes type I bipolar
Low incidence of weight gain
Can cause GI sx, parkinsonism, and seizures.
Don’t use if CrCl < 30
Iloperidone
Low risk of metabolic side effects
QTc prolongation
Lurasidone
Low risk of metabolic/cardiac effects
Take with minimum of 350 calories of food
Adjust for renal, hepatic, and CYP3A4 inhibitors
Olanzapine
High risk of diabetes
Olanzapine pamoate - LAI, REMS for delirium/sedation
Can only be administered in an approved institution
Quetiapine
Somnolence, weight gain
Low risk of EPS
Also indicated for depression associated with bipolar
Risperidone
Tolerated better than haloperidol
Weight gain, sexual dysfunction, hyperprolactinemia
Monthly SC injection, no PO overlap required
Ziprasidone
QTc prolongation
Take with 500 calories of food
Warning - skin reactions such as eosinophila and systemic syndrome (DRESS)
Schizophrenia
SGA > FGA
*SGA may reduce negative symptoms/affect mood due to additional serotonin effects
Can use benzo’s for acute phase (agitation/anxiety) but careful due to risk of substance abuse behaviors